Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553895 | 0.90 | KMT2A (0.44) | CRHR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7557861 | 0.89 | KMT2A (0.43) | CRHR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7076685 | 0.79 | CRHR1 (0.46) | CRHR1TP53 | |
| SCHEMBL7561708 | 0.78 | CRHR1 (0.44) | CRHR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7075873 | 0.77 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7557828 | 0.75 | CDK1 (0.40) | CRHR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7076556 | 0.72 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7560074 | 0.70 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7071736 | 0.70 | KDM4E (0.38) | CRHR1 | |
| SCHEMBL7560082 | 0.68 | CRHR1 (0.53) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | claimed |
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6284766-B1 | DIAGNOSIS, THERAPY OF STRESS DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | HTR1D, CRHR1, HTR1A | CRHR1 2/4885MEN1 1722/4885KMT2A 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.